Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
You’ve probably heard that collagen supplements are good for your joints. You may have also heard that they’re basically expensive placebo — a marketing story built on wishful thinking and ground-up animal bones. What if the truth is considerably more interesting than either of those takes? What if the real question isn’t *whether* collagen works for joint health, but *which type*, at *what dose*, and through *what mechanism* — because the answer turns out to matter quite a lot?
To bring you this breakdown, VitacuityAI analysed 1.7 million research papers and selected the 15 most relevant studies on collagen and joint health. Here’s what the evidence actually shows.
Before we get into the findings, it helps to understand what we’re actually talking about — because “collagen” is not one thing.
Collagen is the most abundant structural protein in the human body [15]. It forms the scaffolding of your cartilage, tendons, ligaments and bones. As we age, collagen production declines and the collagen we do produce tends to be lower quality — this is one reason why joints become stiffer, more painful and more vulnerable to wear-and-tear conditions like osteoarthritis (OA), which affects around 242 million people worldwide [12].
When it comes to supplements, two main types dominate the research [1]:
Hydrolysed collagen (also called collagen peptides) is collagen that has been broken down into smaller fragments — short chains of amino acids called peptides — through a process called hydrolysis. These fragments are small enough to be absorbed through the gut wall and, crucially, some of them appear to travel to joint tissues where they may stimulate cartilage cells and reduce inflammation [1].
Native (undenatured) collagen works differently. Rather than acting as a building block, it appears to work through the immune system — specifically by a process called oral tolerance. Small doses of intact collagen (particularly type II) are thought to be recognised by immune cells in the gut, which then dampens down the inflammatory attack on joint cartilage [1][12]. Think of it as teaching your immune system not to treat your own joint tissue as an enemy.
These are genuinely different mechanisms, which is why comparing “collagen” studies without specifying type is a bit like comparing paracetamol and ibuprofen and concluding that “painkillers are inconsistent.”
Evidence grade: Promising to Strong — multiple RCTs with consistent direction, though sample sizes vary
The most practically relevant question for most people is simple: does taking collagen reduce joint pain? Across several recent randomised controlled trials, the answer is a cautious but consistent yes.
A 2025 randomised double-blind placebo-controlled study gave 10g of collagen peptides (molecular weight 1–3 kDa) to adults aged 30–81 with grade II or III knee osteoarthritis [14]. After six months, the collagen group showed significant reductions in pain scores on the visual analogue scale (VAS), improved functional scores on the Lequesne algofunctional index, and meaningfully lower levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) — both markers of inflammation — compared to placebo (p < 0.001). No adverse effects were reported.
A 2024 RCT with 182 participants across a wide age range (18+) tested 5g of specific collagen peptides daily over 12 weeks [2]. The collagen group showed significant reductions in pain at rest and during daily activities, assessed both by physicians and participants using a 10-point numeric rating scale. This is notable because 5g is a relatively modest dose — and it still moved the needle.
A 2025 RCT involving 80 participants with chronic knee pain used a hydrolysed collagen-based food supplement formula over a longer period [6]. By week 6, the supplement group showed statistically significant pain reductions compared to placebo in the hours following exercise, and improvements were also seen in KOOS scores (a standard measure of knee symptoms) and WOMAC functional capacity scores. Quality of life measures also improved significantly in the supplement group.
A smaller 2025 trial (31 participants with grade 2–3 OA) found that eight weeks of a multi-collagen supplement (types I, II and III) produced significant improvements across virtually every pain and quality-of-life measure tested — including VAS, WOMAC, KOOS, Oxford Knee Score and SF-12 — compared to placebo [7]. Balance (Berg Balance Scale) and six-minute walking distance also improved significantly.
Taken together, these trials consistently point in the same direction. The limitations are real — sample sizes are often in the tens to low hundreds, study durations range from 8 weeks to 6 months, and the formulations tested vary. But the consistency across independent trials using different populations, different doses and different outcome measures is genuinely encouraging.
Evidence grade: Promising — one well-designed 5-arm RCT
One of the most intriguing recent findings comes from a 2024 five-arm double-blind RCT comparing different doses of a high-functional “Type J” bovine collagen peptide against conventional collagen peptides and placebo, over 90 days [3]. The researchers measured WOMAC scores, pain scales, quality of life, cartilage breakdown markers (serum CTX-II), and MRI-based knee scoring (MOAKS).
The headline finding? Type J collagen at just 2.5g performed as well as conventional collagen peptides at 10g. Both significantly improved WOMAC scores, quality of life, CTX-II levels and MRI outcomes. This suggests that the *type and quality* of collagen peptide — its specific peptide sequences and bioactivity — may matter more than simply taking a larger amount of a standard product. If you’re choosing a collagen supplement, this research suggests it’s worth looking at the specific product formulation, not just the dose on the label.
Evidence grade: Promising — supported by human and animal trials, but mechanisms in humans need further clarification
Native, undenatured type II collagen (UC-II) is quite distinct from hydrolysed collagen in how it’s thought to work. Rather than providing amino acid building blocks, it appears to act through immune modulation — the oral tolerance mechanism described earlier [1][12].
A 2022 study specifically investigating undenatured type II collagen on knee joint function [4] found improvements in range of motion and joint flexibility. A 2023 review of the research on undenatured type II collagen noted that oral administration could significantly improve OA symptoms, though the authors were careful to flag that the activity of UC-II is affected by source material, the degree of denaturation, dosing protocols and the way the intervention is delivered [12].
The immune mechanism is genuinely interesting from a scientific standpoint: type II collagen in joint cartilage is one of the targets of the inflammatory process in OA. By exposing the gut immune system to small amounts of intact type II collagen, the hypothesis is that you can shift the immune response from attacking the cartilage to tolerating it [10]. Reviews of the mechanism suggest that T-lymphocytes and B-cells are centrally involved in regulating this response [10]. What’s also notable is that the same molecule — type II collagen — has been used in animal studies to *induce* arthritis (by triggering an immune attack) and to *suppress* it (through tolerance), depending entirely on how it’s administered and whether the structure is preserved [10]. This underlines just how structure-dependent collagen biology really is.
Evidence grade: Promising — early biomarker data from RCTs
Pain scores are subjective. What about objective markers of what’s happening inside the joint?
The 2024 five-arm RCT mentioned above [3] measured serum CTX-II — a biomarker of type II collagen breakdown in cartilage — and found significant reductions in the collagen groups compared to placebo, including MRI-based improvements in cartilage scoring (MOAKS). This is meaningful because it suggests collagen supplementation may not just be masking pain, but potentially slowing some of the underlying tissue breakdown.
The 2025 RCT [14] similarly found reductions in inflammatory markers CRP and ESR alongside pain reduction — again suggesting a biological effect beyond subjective symptom relief.
It would be premature to call this “disease-modifying” — and it’s important to note that no drugs have yet been approved as disease-modifying for OA [1]. But the direction of this biomarker data is worth watching.
Evidence grade: Promising — one well-designed 24-week RCT
Joint pain doesn’t exist in isolation — it limits movement, reduces exercise, and over time leads to muscle weakness and reduced quality of life. A 24-week randomised double-blind placebo-controlled trial in 90 adults aged 45–65 with osteoarticular discomfort investigated the effects of 10g of hydrolysed collagen (enriched with vitamins and minerals) versus placebo, while participants also followed a twice-weekly exercise programme [13].
The collagen group showed significantly greater improvements in countermovement jump performance (a measure of lower limb neuromuscular power, p = 0.032) compared to the placebo group, with men showing greater gains than women. Strikingly, 72.1% of the collagen group reported improved musculoskeletal discomfort after 24 weeks, compared to only 10.3% of the placebo group. The researchers suggested the mechanism may involve connective tissue remodelling and increased tendon elasticity, not just muscle effects directly.
The addition of a supervised exercise programme means we can’t isolate the collagen effect entirely — but the differential between groups (72% vs. 10% reporting improvement) is hard to dismiss.
Evidence grade: Promising — systematic review with important caveats around study heterogeneity
A 2025 systematic review searched four major academic databases, screened 4,246 articles, and included 36 RCTs meeting strict criteria for type I hydrolysed collagen supplementation [5]. The findings on joint health were notably positive: across included studies, outcomes included pain reduction, improvements in clinical parameters, increased physical mobility and enhanced ankle function. The review concluded that collagen supplementation shows “promising results” for joint health.
The honest caveat from the review itself: heterogeneity across studies — different populations, protocols, durations and outcome measures — limits how broadly these findings can be generalised. Bone health findings were less clear. Muscle health findings were inconsistent unless combined with exercise.
A separate 2025 systematic review and meta-analysis specifically focused on knee OA and collagen [8] reached broadly similar conclusions, supporting the clinical efficacy of collagen-based supplements for knee OA symptoms.
A 2025 real-world observational study [11] of 186 patients taking a hydrolysed collagen combination supplement (3,000mg collagen alongside chondroitin, glucosamine, turmeric and devil’s claw) over six months found a mean VAS pain reduction of 1.99 points at three months and 3.57 points at six months — meaningful reductions on a 10-point scale. However, this was an open, non-placebo-controlled study, so it cannot isolate the collagen effect from the other ingredients or from natural disease progression.
Here’s where intellectual honesty matters. The collagen research for joint health is genuinely encouraging — but it’s not without gaps and limitations.
We don’t have a standardised collagen. Different studies use different types (I, II, III, native, hydrolysed), different sources (bovine, marine, chicken), different molecular weights and different doses. This makes direct comparison between studies difficult and means a finding from one product can’t automatically be applied to another [1][5].
Long-term data is thin. Most trials run for 8–24 weeks. Osteoarthritis is a decades-long condition. We don’t yet know whether the benefits seen in short trials are maintained, whether they slow structural joint deterioration over years, or what the optimal long-term dose looks like [1][5].
The “disease-modifying” question is open. While biomarker data from a few trials is intriguing [3][14], no supplement — collagen or otherwise — has been approved as a disease-modifying treatment for OA. The biomarker improvements are promising signals, not confirmed proof of structural protection [1].
Sample sizes remain modest. Several of the individual trials cited here had fewer than 100 participants. Even the larger ones (182 participants [2], 186 patients [11]) are relatively small for the questions being asked. Larger, longer, independently funded trials are needed.
Many studies used combination products. The 2025 observational study [11], for example, combined collagen with chondroitin, glucosamine, turmeric and devil’s claw. When supplements are stacked, it becomes harder to attribute the effect to any single ingredient.
The mechanism in humans needs more clarity. Particularly for undenatured type II collagen, the oral tolerance mechanism is biologically plausible and supported by animal studies, but the exact pathway in humans — how it activates tolerance, which immune cells are involved, and how this translates to clinical benefit — is not yet fully mapped [10][12].
Not everyone responds the same way. The 24-week fitness trial [13] found men responded more strongly than women to some measures. Factors like baseline collagen status, diet, age and exercise habits almost certainly influence outcomes.
So what would a sensible, well-informed person actually do with all of this?
Here’s the practical picture: collagen is one of the better-evidenced supplements in the joint health space. It’s not a miracle and it’s not junk science. Multiple RCTs — admittedly imperfect ones — consistently show meaningful pain reduction, improved function, and some promising biomarker effects in people with knee OA and general joint discomfort. The systematic review evidence points the same way. The biological mechanisms are plausible and increasingly well characterised.
On safety: Across all the trials reviewed here, collagen supplementation was consistently reported as safe and well-tolerated, with no adverse effects noted in multiple studies [2][6][7][14]. This is a low-risk intervention.
On dose: Most trials showing positive effects used doses between 5g and 10g of hydrolysed collagen daily [2][6][13][14]. The intriguing Type J research [3] suggests that more bioactive formulations may be effective at lower doses (2.5g), so quality of the product likely matters as much as quantity.
On type: If you have OA or significant joint inflammation, there may be a case for trying native undenatured type II collagen (for its immune-modulating mechanism) alongside or instead of hydrolysed collagen (for its cartilage-supporting peptide action). These are genuinely different tools [1].
On timing and expectations: This is not a rapid-acting supplement. Most trial benefits appeared over 8–24 weeks of consistent daily use. Think of it as a slow, structural investment — not a painkiller. Combining it with regular exercise, even gentle twice-weekly resistance or movement work, appears to enhance results [13].
On cost: Collagen supplements are widely available at reasonable prices, particularly bovine hydrolysed collagen. Given the safety profile, the consistent trial direction, and the fact that there are currently no approved disease-modifying treatments for OA [1], the risk-benefit calculation for a healthy adult with joint discomfort is clearly in favour of trying it. You don’t need a doctor’s prescription. You don’t need a blood test first. You just need consistency.
The bottom line? Collagen isn’t going to reverse decades of joint wear overnight. But the evidence — across 36 RCTs in one systematic review alone [5] — consistently suggests it can reduce pain, improve function and possibly slow some of the biological processes driving joint deterioration. For a safe, accessible, reasonably priced supplement, that’s a meaningful case for including it in your daily routine.
[1] Narrative review: Native and hydrolyzed collagen for joint health — mechanisms, preclinical and clinical evidence (2023). DOI: 10.3390/nu15061332 | PubMed: https://pubmed.ncbi.nlm.nih.gov/36986062/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058045/
[2] Impact of Specific Bioactive Collagen Peptides on Joint Discomforts in the Lower Extremity during Daily Activities: A Randomized Controlled Trial (2024). PubMed: https://pubmed.ncbi.nlm.nih.gov/38928934/
[3] Double-blind randomized 5-arm clinical trial of high-functional “Wellnex” Type J bovine collagen peptides in knee osteoarthritis (2024). DOI: 10.1177/19476035231221211 | PubMed: https://pubmed.ncbi.nlm.nih.gov/38235711/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520019/
[4] Undenatured Type II Collagen: Joint flexibility, knee joint function and range of motion (2022). DOI: 10.1089/jicm.2021.0365 | PubMed: https://pubmed.ncbi.nlm.nih.gov/35377244/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232232/
[5] Systematic review of type I hydrolyzed collagen supplementation on bones, muscles and joints — 36 RCTs included (2025). DOI: 10.52965/001c.129086 | PubMed: https://pubmed.ncbi.nlm.nih.gov/39980497/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842160/
[6] Effects of a Food Supplement Containing Hydrolyzed Collagen on Pain Perception, Joint Range, and Quality of Life in People with Chronic Knee Pain (2025). DOI: 10.3390/diseases13070189 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40709979/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293524/
[7] Double-blind RCT: Naturagen® 4 Joint (types I, II and III collagen) in grade 2–3 knee osteoarthritis, 8 weeks (2025). DOI: 10.52312/jdrs.2025.1965 | PubMed: https://pubmed.ncbi.nlm.nih.gov/39719905/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734850/
[8] Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis of randomised controlled trials (2025). PubMed: https://pubmed.ncbi.nlm.nih.gov/39212129/
[9] Evaluation of the Efficacy and Safety of CollaSel PRO (2025). DOI: 10.3390/jcm14113655 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40507417/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12156922/
[10] Review: Arthritogenic and anti-arthritogenic properties of collagen — mechanism and immune regulation (2022). DOI: 10.3390/bioengineering9070321 | PubMed: https://pubmed.ncbi.nlm.nih.gov/35877372/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311863/
[11] Observational study: Hydrolyzed collagen combination supplement (with chondroitin, glucosamine, turmeric, devil’s claw) in knee and hip OA over 6 months, n=186 (2024). DOI: 10.1080/19390211.2023.2284982 | PubMed: https://pubmed.ncbi.nlm.nih.gov/38180010/
[12] Review: Undenatured type II collagen — extraction, structure, stability and role in improving osteoarthritis (2023). DOI: 10.1016/j.arr.2023.102080 | PubMed: https://pubmed.ncbi.nlm.nih.gov/37774932/
[13] Effects of 24 weeks of collagen supplementation in active adults: Impact on body composition, neuromuscular and cardiorespiratory fitness (2025). DOI: 10.5114/biolsport.2025.147017 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40756568/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314484/
[14] Oral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis: Results from a randomized, double-blind, placebo-controlled study (2025). DOI: 10.1016/j.conctc.2024.101424 | PubMed: https://pubmed.ncbi.nlm.nih.gov/39839727/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745964/
[15] Review: Oral collagen supplementation — skin aging, musculoskeletal health and biosensing approaches, integrating over 60 clinical studies (2025). DOI: 10.3389/fnut.2025.1716166 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41459089/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12739960/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
